Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide drug-device therapies for respiratory infections, filed on Tuesday with the SEC to raise up to $36 million in an initial public offering.
The Rehovot, Israel-based company, which was founded in 2011, plans to list on the Nasdaq under the symbol AITP. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
